TY - JOUR
T1 - European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
AU - Caers, Jo
AU - Garderet, Laurent
AU - Kortüm, K. Martin
AU - O'Dwyer, Michael E.
AU - van de Donk, Niels W. C. J.
AU - Binder, Mascha
AU - Dold, Sandra Maria
AU - Gay, Francesca
AU - Corre, Jill
AU - Beguin, Yves
AU - Ludwig, Heinz
AU - Larocca, Alessandra
AU - Driessen, Christoph
AU - Dimopoulos, Meletios A.
AU - Boccadoro, Mario
AU - Gramatzki, Martin
AU - Zweegman, Sonja
AU - Einsele, Hermann
AU - Cavo, Michele
AU - Goldschmidt, Hartmut
AU - Sonneveld, Pieter
AU - Delforge, Michel
AU - Auner, Holger W.
AU - Terpos, Evangelos
AU - Engelhardt, Monika
PY - 2018
Y1 - 2018
N2 - The diagnosis of multiple myeloma can be challenging, even for experienced physicians, and requires close collaboration between numerous disciplines (orthopedics, radiology, nuclear medicine, radiation therapy, hematology and oncology) before the final diagnosis of myeloma is made. The definition of multiple myeloma is based on the presence of clinical, biochemical, histopathological, and radiological markers of disease. Specific tests are needed both at presentation and during follow-up in order to reach the correct diagnosis and characterize the disease precisely. These tests can also serve prognostic purposes and are useful for follow-up of myeloma patients. Molecular analyses remain pivotal for defining high-risk myeloma and are used in updated patient stratifications, while minimal residual disease assessment via flow cytometry, molecular techniques and radiological approaches provides additional prognostic information on patients' long-term outcome. This pivotal information will guide our future treatment decisions in forthcoming clinical trials. The European Myeloma Network group updated their guidelines on different diagnostic recommendations, which should be of value to enable appropriate use of the recommendations both at diagnosis and during follow-up.
AB - The diagnosis of multiple myeloma can be challenging, even for experienced physicians, and requires close collaboration between numerous disciplines (orthopedics, radiology, nuclear medicine, radiation therapy, hematology and oncology) before the final diagnosis of myeloma is made. The definition of multiple myeloma is based on the presence of clinical, biochemical, histopathological, and radiological markers of disease. Specific tests are needed both at presentation and during follow-up in order to reach the correct diagnosis and characterize the disease precisely. These tests can also serve prognostic purposes and are useful for follow-up of myeloma patients. Molecular analyses remain pivotal for defining high-risk myeloma and are used in updated patient stratifications, while minimal residual disease assessment via flow cytometry, molecular techniques and radiological approaches provides additional prognostic information on patients' long-term outcome. This pivotal information will guide our future treatment decisions in forthcoming clinical trials. The European Myeloma Network group updated their guidelines on different diagnostic recommendations, which should be of value to enable appropriate use of the recommendations both at diagnosis and during follow-up.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055858865&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30171031
U2 - 10.3324/haematol.2018.189159
DO - 10.3324/haematol.2018.189159
M3 - Article
C2 - 30171031
VL - 103
SP - 1772
EP - 1784
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 11
ER -